Grant A. McArthur

79.7k total citations · 9 hit papers
395 papers, 26.8k citations indexed

About

Grant A. McArthur is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Grant A. McArthur has authored 395 papers receiving a total of 26.8k indexed citations (citations by other indexed papers that have themselves been cited), including 255 papers in Molecular Biology, 245 papers in Oncology and 81 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Grant A. McArthur's work include Melanoma and MAPK Pathways (163 papers), Cutaneous Melanoma Detection and Management (92 papers) and Cancer Immunotherapy and Biomarkers (58 papers). Grant A. McArthur is often cited by papers focused on Melanoma and MAPK Pathways (163 papers), Cutaneous Melanoma Detection and Management (92 papers) and Cancer Immunotherapy and Biomarkers (58 papers). Grant A. McArthur collaborates with scholars based in Australia, United States and United Kingdom. Grant A. McArthur's co-authors include Antoni Ribas, Keith T. Flaherty, Jeffrey A. Sosman, Igor Puzanov, Paul B. Chapman, K. B. Nolop, Kevin B. Kim, Georgina V. Long, Joseph F. Grippo and Richard J. Lee and has published in prestigious journals such as Nature, New England Journal of Medicine and Cell.

In The Last Decade

Grant A. McArthur

390 papers receiving 26.4k citations

Hit Papers

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma 2006 2026 2012 2019 2010 2006 2010 2014 2017 500 1000 1.5k 2.0k 2.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
    2010 2.6k citations Igor Puzanov, Kevin B. Kim et al. profile →
  2. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
    2006 1.9k citations George D. Demetri, Manisha H. Shah et al. profile →
  3. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
    2010 1.6k citations Grant A. McArthur, Jeffrey A. Sosman et al. profile →
  4. Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma
    2014 1.5k citations James Larkin, Paolo A. Ascierto et al. profile →
  5. Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
    2017 1.4k citations Georgina V. Long, Grant A. McArthur et al. profile →
  6. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study
    2018 655 citations Georgina V. Long, Grant A. McArthur et al. profile →
  7. Prognostic Significance of p16 INK4A and Human Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROG 02.02 Phase III Trial
    2010 571 citations Danny Rischin, Richard J. Young et al. Journal of Clinical Oncology profile →
  8. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
    2020 442 citations Karl D. Lewis, Yibing Yan et al. profile →
  9. Melanoma
    2015 441 citations Dirk Schadendorf, Grant A. McArthur et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Grant A. McArthur Australia 74 15.2k 15.0k 5.4k 3.8k 3.1k 395 26.8k
Paolo A. Ascierto Italy 75 11.4k 0.7× 18.1k 1.2× 3.5k 0.6× 7.1k 1.9× 2.5k 0.8× 757 25.2k
Jeffrey A. Sosman United States 73 15.5k 1.0× 16.2k 1.1× 8.3k 1.6× 6.9k 1.8× 5.0k 1.6× 347 28.5k
Keith T. Flaherty United States 92 23.3k 1.5× 24.8k 1.7× 6.3k 1.2× 7.1k 1.9× 5.7k 1.8× 518 39.7k
David B. Solit United States 82 15.6k 1.0× 10.6k 0.7× 5.6k 1.0× 2.4k 0.6× 4.8k 1.6× 365 26.2k
Ravi Salgia United States 90 12.5k 0.8× 10.6k 0.7× 8.4k 1.6× 3.0k 0.8× 3.7k 1.2× 626 27.5k
Howard A. Burris United States 89 13.0k 0.9× 25.4k 1.7× 10.7k 2.0× 3.3k 0.9× 6.2k 2.0× 741 38.2k
Georgina V. Long Australia 85 16.6k 1.1× 25.4k 1.7× 5.2k 1.0× 9.2k 2.4× 3.5k 1.1× 684 34.4k
José Baselga Spain 94 17.3k 1.1× 34.9k 2.3× 13.6k 2.5× 2.8k 0.8× 9.4k 3.1× 273 49.5k
Geoffrey I. Shapiro United States 79 12.9k 0.8× 12.8k 0.9× 7.8k 1.5× 2.0k 0.5× 3.0k 1.0× 500 23.0k
Éric Raymond France 71 8.8k 0.6× 10.9k 0.7× 4.6k 0.9× 1.4k 0.4× 3.0k 1.0× 369 22.4k

Countries citing papers authored by Grant A. McArthur

Since Specialization
Citations

This map shows the geographic impact of Grant A. McArthur's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Grant A. McArthur with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Grant A. McArthur more than expected).

Fields of papers citing papers by Grant A. McArthur

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Grant A. McArthur. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Grant A. McArthur. The network helps show where Grant A. McArthur may publish in the future.

Co-authorship network of co-authors of Grant A. McArthur

This figure shows the co-authorship network connecting the top 25 collaborators of Grant A. McArthur. A scholar is included among the top collaborators of Grant A. McArthur based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Grant A. McArthur. Grant A. McArthur is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hieken, Tina J., et al.. (2023). Neoadjuvant Immunotherapy in Melanoma: The Paradigm Shift. American Society of Clinical Oncology Educational Book. 43(43). e390614–e390614. 17 indexed citations
2.
Degeling, Koen, Nancy N. Baxter, Jon Emery, et al.. (2021). An inverse stage‐shift model to estimate the excess mortality and health economic impact of delayed access to cancer services due to the COVID‐19 pandemic. Asia-Pacific Journal of Clinical Oncology. 17(4). 359–367. 56 indexed citations
3.
Kusnadi, Eric, Anna Trigos, Carleen Cullinane, et al.. (2020). Reprogrammed mRNA translation drives resistance to therapeutic targeting of ribosome biogenesis. The EMBO Journal. 39(21). e105111–e105111. 28 indexed citations
4.
Ribas, Antoni, Adil Daud, Anna C. Pavlick, et al.. (2019). Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF -Mutant Melanoma. Clinical Cancer Research. 26(1). 46–53. 30 indexed citations
5.
Zhang, Xiaomeng, Jian Tang, Ismael A. Vergara, et al.. (2019). Somatic Hypermutation of the YAP Oncogene in a Human Cutaneous Melanoma. Molecular Cancer Research. 17(7). 1435–1449. 29 indexed citations
6.
Wongchenko, Matthew, Grant A. McArthur, Brigitte Dréno, et al.. (2017). Gene Expression Profiling in BRAF -Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib. Clinical Cancer Research. 23(17). 5238–5245. 28 indexed citations
7.
Teo, Zhi L., Sathana Dushyanthen, Franco Caramia, et al.. (2017). Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer. Cancer Research. 77(22). 6340–6352. 148 indexed citations
8.
Kim, Kevin B., Richard Kefford, Anna C. Pavlick, et al.. (2012). Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF -Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor. Journal of Clinical Oncology. 31(4). 482–489. 356 indexed citations
9.
Demetri, George D., Patrick Schöffski, Manisha H. Shah, et al.. (2012). Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure. Clinical Cancer Research. 18(11). 3170–3179. 102 indexed citations
10.
Wall, Meaghan, Gretchen Poortinga, Kym L. Stanley, et al.. (2012). The mTORC1 Inhibitor Everolimus Prevents and Treats Eμ- Myc Lymphoma by Restoring Oncogene-Induced Senescence. Cancer Discovery. 3(1). 82–95. 52 indexed citations
11.
Zimmer, Lisa, Uwe Hillen, Elisabeth Livingstone, et al.. (2012). Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective BRAF Inhibition. Journal of Clinical Oncology. 30(19). 2375–2383. 167 indexed citations
12.
Le, Quynh‐Thu, Richard Fisher, Kelly S. Oliner, et al.. (2012). Prognostic and Predictive Significance of Plasma HGF and IL-8 in a Phase III Trial of Chemoradiation with or without Tirapazamine in Locoregionally Advanced Head and Neck Cancer. Clinical Cancer Research. 18(6). 1798–1807. 41 indexed citations
13.
Kinross, Kathryn M., Daniel V. Brown, Margarete Kleinschmidt, et al.. (2011). In Vivo Activity of Combined PI3K/mTOR and MEK Inhibition in a KrasG12D ; Pten Deletion Mouse Model of Ovarian Cancer. Molecular Cancer Therapeutics. 10(8). 1440–1449. 62 indexed citations
14.
Azad, Arun, Susan Jackson, Carleen Cullinane, et al.. (2011). Inhibition of DNA-Dependent Protein Kinase Induces Accelerated Senescence in Irradiated Human Cancer Cells. Molecular Cancer Research. 9(12). 1696–1707. 51 indexed citations
15.
Young, Richard J., Danny Rischin, Richard Fisher, et al.. (2011). Relationship between Epidermal Growth Factor Receptor Status, p16INK4A, and Outcome in Head and Neck Squamous Cell Carcinoma. Cancer Epidemiology Biomarkers & Prevention. 20(6). 1230–1237. 70 indexed citations
16.
Rischin, Danny, Richard J. Young, Richard Fisher, et al.. (2010). Prognostic Significance of p16 INK4A and Human Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROG 02.02 Phase III Trial. Journal of Clinical Oncology. 28(27). 4142–4148. 571 indexed citations breakdown →
17.
Cullinane, Carleen, Anthony Natoli, Nelly Conus, et al.. (2010). Preclinical Evaluation of Nilotinib Efficacy in an Imatinib-Resistant KIT-Driven Tumor Model. Molecular Cancer Therapeutics. 9(5). 1461–1468. 27 indexed citations
18.
Davis, Ian D., Richard Kefford, Michael Millward, et al.. (2009). Clinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa Trial. Clinical Cancer Research. 15(6). 2123–2129. 120 indexed citations
19.
Davis, Ian D., Birte K. Skrumsager, Jonathan Cebon, et al.. (2007). An Open-Label, Two-Arm, Phase I Trial of Recombinant Human Interleukin-21 in Patients with Metastatic Melanoma. Clinical Cancer Research. 13(12). 3630–3636. 132 indexed citations
20.
Deans, Andrew J., Kum Kum Khanna, Carolyn J. McNees, et al.. (2006). Cyclin-Dependent Kinase 2 Functions in Normal DNA Repair and Is a Therapeutic Target in BRCA1-Deficient Cancers. Cancer Research. 66(16). 8219–8226. 93 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paolo A. Ascierto Breakdown of academic impact, for papers by Jeffrey A. Sosman Breakdown of academic impact, for papers by Keith T. Flaherty Breakdown of academic impact, for papers by David B. Solit Breakdown of academic impact, for papers by Ravi Salgia Breakdown of academic impact, for papers by Howard A. Burris Breakdown of academic impact, for papers by Georgina V. Long Breakdown of academic impact, for papers by José Baselga Breakdown of academic impact, for papers by Geoffrey I. Shapiro Breakdown of academic impact, for papers by Éric Raymond
Rankless by CCL
2026